Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart…
SCVC will provide theCaRi-HeartAI-based cardiac assessment as a central part of the organisations 's employee wellness initiative for UK employers. Designed to provide industry-leading preventative care for employees and directors, the programme includes a package of advanced health screening tests delivered in SCVC's one-stop clinical diagnostic centre (CDC). In combination with the programme's other tests, Cari-Heart provides the ability to predict future heart attacks and...
PR Newswire
23/04/2024
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to…
To date, of the 10 participating patients, two patients have been dosed for more than one year and eight additional patients have been dosed for six months, all without serious side effects. All patients have either stabilized or improved on treatment with foralumab, and no patients have declined in key clinical measures. Additionally, 70% of these patients have seen a measurable improvement in fatigue. These data are the first to combine PET imaging with a novel ligand, immune-biomarkers,...
Nasdaq GlobeNewswire
23/04/2024
Clario awarded SAS Global Service Provider Partner of the Year
Clario has consistently demonstrated its expertise in developing and integrating advanced technological solutions to meet the evolving clinical trial needs of its customers. Clario's services, combined with SAS technology, standardize clinical data for regulatory compliance purposes. This standardization streamlines the regulatory review process, ensures data integrity, and facilitates compliance with regulatory standards set by entities such as the Food and Drug Administration (FDA) and the…
PR Newswire
23/04/2024
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored…
–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee– –Safety and clinical outcomes support the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01's potential for use in diverse cancer indications– ROCKVILLE, Md., April23, 2024(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed...
Nasdaq GlobeNewswire
23/04/2024
Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare…
Global Q supports leading pharma, medtech and biotech companies by providing comprehensive access to linked and standardized workflow-ready data via its SaaS platform, Optiqs360 Digital™. The platform includes MediGPT - WorkCenter™ and MediGPT - IntelliWriter™, solutions that provide clients with interconnected data visibility and common user interfaces, across internal and external sources of record. The tools support the complex workflows and reporting needs of clinical, regulatory, product…
PR Newswire
23/04/2024
Zayed Sustainability Prize's Beyond2020 Initiative Deploys Life-saving Digital…
The initiative will significantly enhance access to high quality healthcare for women in the region. 8,000 tests will be conducted annually using the AI-based mammography services, which have been deployed in Juan Pablo II Medical Centre in Cartago, with plans to deploy the services in additional health facilities in the future. The initiative will significantly enhance access to high quality healthcare for women in the region. 8,000 tests will be conducted annually using the AI-based...
PR Newswire
23/04/2024
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the…
CDR-Life Inc.today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager ®technology's...
Nasdaq GlobeNewswire
23/04/2024
University medical centers in Germany choose Sectra's radiology solution to…
Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in Germany managing 300,000 and 600,000 radiology exams a year. The two separate contracts for Sectra's radiology solution were both signed during the third quarter of Sectra's 2023/2024 fiscal year. Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in...
PR Newswire
23/04/2024
Today is the first day of the subscription period in SciBase rights issue
Summary of the Rights Issue Summary of the Rights Issue ProspectusComplete information regarding the Rights Issue and information about the Company can be found in the prospectus published on19 April 2024. The prospectus is available on the Company's website ( http://investors.scibase.se/en ), on Vator Securities' website ( www.vatorsecurities.se ) and on the Swedish Financial Supervisory Authority's website ( www.fi.se ). Timetable for the Rights Issue Advisors ...
PR Newswire
23/04/2024
Sequana Medical announces the Annual and Extraordinary General Meetings of…
PRESS RELEASE REGULATED INFORMATION23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetingsof Shareholders on 23 May 2024 Publication of Annual Report 2023Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company...
Nasdaq GlobeNewswire
23/04/2024
Sequana Medical announces the Annual and Extraordinary General Meetings of…
PRESS RELEASE REGULATED INFORMATION23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetingsof Shareholders on 23 May 2024 Publication of Annual Report 2023Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company...
Nasdaq GlobeNewswire
23/04/2024
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally…
Request Sample of the Report on Electroceuticals/Bioelectric Medicine Market Forecast - https://www.alliedmarketresearch.com/request-sample/A07649 Request Sample of the Report on Electroceuticals/Bioelectric Medicine Market Forecast -https://www.alliedmarketresearch.com/request-sample/A07649 Prime determinants of growth Growing adoption of electroceuticals, advancements in technologies and presence of key players are the factors that drive the growth of the global...
PR Newswire
23/04/2024
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune…
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaPivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi's robust immunology pipeline and a testament to Sanofi's ability to...
Nasdaq GlobeNewswire
23/04/2024
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY…
Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% (cc 1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum includingEntresto(+36% cc),Cosentyx(+25% cc),Kesimpta(+66% cc),Kisqali(+54% cc),Pluvicto(+47% cc) andLeqvio(+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net salesOperating income grew +39% (cc, +29% USD) and net…
Nasdaq GlobeNewswire
23/04/2024
Sequana Medical announces Annual General Meeting of Shareholders on 25 May…
PRESS RELEASE REGULATED INFORMATION23 April 2024, 07:00 am CET Publication of Annual Report 2023Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings of Shareholders on Thursday, 23 May 2024...
Nasdaq GlobeNewswire
23/04/2024
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, including an extension of the maturity by six months.Allschwil, Switzerland – April 23, 2024Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350)...
Nasdaq GlobeNewswire
23/04/2024
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION…
"Our goal is to transform the treatment of T1D, and our stem cell-derived, fully differentiated islet cell VX-880 Ph 1/2 program has demonstrated this potential," said Morrey Atkinson Ph.D., Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, at Vertex. "We're excited to explore TreeFrog's C-StemTM to scale up stem cell production and deliver for the large number of people living with T1D." "Our…
PR Newswire
23/04/2024
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
The first trial is SOLAR-STAGE : a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable intermediate-risk, high-risk or very-high-risk prostate cancer electing to undergo radical prostatectomy with pelvic lymph node dissection. The second study, SOLAR-RECUR : a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in...
Nasdaq GlobeNewswire
23/04/2024
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a…
Key Takeaways from the Dry Age-related Macular Degeneration Market Report Key Takeaways from the Dry Age-related Macular Degeneration Market Report Discover which therapies are expected to grab the major dry AMD market share @ Dry Age-related Macular Degeneration Market Report Dry Age-related Macular Degeneration Overview Dry AMD, a prevalent ocular condition affecting individuals aged 50 and above, leads to a decline in central vision clarity due to macular thinning. The...
PR Newswire
22/04/2024
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy…
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft– – The observed synergy emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer– ROCKVILLE, Md., April22, 2024(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer...
Nasdaq GlobeNewswire
22/04/2024
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene…
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April22, 2024(GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene...
Nasdaq GlobeNewswire
22/04/2024
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for…
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2]. ...
PR Newswire
22/04/2024
Report of transactions of shares and related securities of Bavarian Nordic by…
COPENHAGEN, Denmark, April 22, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.The transactions concern the vesting of restricted stock units (RSUs) awarded to members of the Board of Directors of Bavarian Nordic A/S as part of their remuneration for 2021, and in accordance with the decision by...
Nasdaq GlobeNewswire
22/04/2024
LABCONNECT ACQUIRES SCIENTIFIC CONSULTANCY A4P
A4P is headquartered in Discovery Park, Sandwich, Kent, UK, with a wholly-owned subsidiary in Appenzell, Switzerland. With core expertise in regulated bioanalysis and genomics, biomarker strategy, personalized healthcare, biosample operations and bespoke logistics solutions, A4P serves a wide variety of clients across a broad range of therapeutic areas. A4P is headquartered in Discovery Park, Sandwich,Kent, UK, with a wholly-owned subsidiary in Appenzell,Switzerland. With core expertise...
PR Newswire
22/04/2024
Altri Comunicati
